三重激動劑 Retatrutide Retatrutide

INT-retatrutide-001 3 個適應症被研究

C 3

適應症與證據等級

肥胖 Obesity

C 🟠 C 薄弱證據附警語發布

→

非酒精性脂肪肝 NAFLD / MASLD

C 🟠 C 薄弱證據附警語發布

→

第二型糖尿病 Type 2 Diabetes

C 🟠 C 薄弱證據附警語發布

→

法規與權威立場 (L4)

L4a · US FDA

立場：cautious

Retatrutide is not currently approved by the FDA and is considered an investigational medication, with Eli Lilly currently evaluating its safety and efficacy in clinical trials.

來源 ↗

L4b · EU EFSA

立場：neutral

Retatrutide is not currently approved by the FDA and is considered an investigational medication.

來源 ↗

L4c · UK NHS

立場：not_addressed

L4d · TW TFDA / 衛福部

立場：cautious

Retatrutide is not currently approved by the FDA and is considered an investigational medication, with Eli Lilly currently evaluating its safety and efficacy in clinical trials.

來源 ↗

L4e · WHO

立場：not_addressed

市場與行銷 (L10)

L10a · TW Market Channels

L10b · TW Legal Identity (TFDA)

L10c · TW Community (PTT/Dcard/Mobile01)